Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

PASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.


'/>"/>

SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 Semiconductor industry leader ... Light-based Technologies (IYL 2015) visionary John Dudley were ... the international society for optics and photonics , last ... and Dudley along with other awards announced earlier this ... by James Harrington, during a gala banquet Wednesday evening ...
(Date:9/2/2014)... detailed studies of what happens on the surface of ... other applications. A group of researchers from Lund University ... form across a large number of vertical nanowires, known ... of a cell and its surroundings takes place through ... that holds the cell together and that largely comprises ...
(Date:9/2/2014)... 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") today ... for protecting personal data in Clinical Study Reports ... others. The document describes an approach to apply ... and other related clinical trial documents, and is ... of the TransCelerate CSR Redaction approach is to ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014 ... announced that the U.S. Patent and Trademark Office (PTO) ... investigational medication being evaluated for weight loss. NB32 is ... bupropion SR. U.S. Patent No. 8,815,889 claims ... naltrexone and bupropion. The patent expires in 2024. If ...
Breaking Biology Technology:Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4Nano-forests to reveal secrets of cells 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... Lumiphore, Inc., a,biotechnology leader in the ... use in high-value applications, announced,that it has ... Inc.,Redwood City, California to apply Lumiphore products ... Under the agreement, Biophor Diagnostics holds the ...
... Inc. (OTC,Bulletin Board: NZYM) announced today the appointment ... on October 1, 2008. Since May,2008, Dr. Farkas ... over 13 years, experience with amino acid derivatives, ... and supply chain,management at Bachem Corporation, Novartis AG ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer ... Chief Executive Officer,and Robert S. Brown, Chief Financial Officer, ... on October 6, 2008 at Le Parker,Meridien Hotel in ... Monday, October 6th at,2:30 p.m. ET. To listen to ...
Cached Biology Technology:Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board 2Synthetech Announces New Director of Manufacturing 2NxStage Medical to Present at JMP Securities Healthcare Focus Conference 2
(Date:9/2/2014)... truth; everyone has a tipping point. We all want to ... benefit is great enough. Now, scientists have confirmed the area ... , The result was published online this week in ... honest, even if lying is beneficial," said Lusha Zhu, the ... Virginia Tech Carilion Research Institute , where she works with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... the U.S. diet showed some modest improvement in the ... in the consumption of unhealthy trans fats, but the ... and the poor. , , An unhealthy diet is ... Eating a healthy diet is an important part of ... trends in diet quality is important because it can ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... its prestigious Clinical and Translational Science Award (CTSA) ... the amount of $29 million over the next ... wireless technology and bioinformatics toward individualizing medicine. ... Health and The Scripps Research Institute in partnership ...
... 22, 2013 More accurate and precise assessment of ... a particular gene that are present in a genome, ... cancer and other diseases including autoimmune disorders. However, ... labor intensive, or prohibitively costly, diminishing their effectiveness in ...
... New research shows that in sub-Saharan Africa the virus responsible ... distances and the African buffalo are important natural reservoirs for ... online open-access journal of the American Society for Microbiology, sheds ... 2 emerged in sub-Saharan Africa and identifies patterns of spread ...
Cached Biology News:NIH awards Scripps Translational Science Institute $29 million grant 2NIH awards Scripps Translational Science Institute $29 million grant 3Bio-Rad's Droplet Digital PCR technology highlighted at ASHG Annual Meeting 2Foot and mouth disease in sub-Saharan Africa moves over short distances, wild buffalo are a problem 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
...
Biology Products: